Cell Envelope Biogenesis in Mycobacterium tuberculosis

结核分枝杆菌的细胞包膜生物发生

基本信息

项目摘要

Project Summary To eradicate tuberculosis (TB), the World Health Organization has proposed reducing TB-related deaths from >1 million to just 50,000 per year by 2025. This 95% reduction will not be met by current programs. Thus, the strategic plan to eliminate TB emphasizes the development of new drugs against the causative bacterium, Mycobacterium tuberculosis (Mtb). The Mtb cell envelope has thus been the target of many efforts to find novel anti-TB therapeutics. However, discovery and validation of new targets is hampered by our limited understanding how the cell envelope is made. Enzymes that make mycomembrane lipids have been characterized, but the mechanism of subsequent lipid incorporation into the mycomembrane remains poorly defined. We and others have identified a pathway that is required for both the transport and the synthesis of diverse mycomembrane lipids. Based on our published work and preliminary data, we hypothesize that the lipoprotein LprG and membrane protein Rv1410c play a broad role in mycomembrane biogenesis by mediating a crucial step in transporting lipids beyond the cytoplasmic membrane and into the mycomembrane. To test this model, we will pursue the following aims: (1) Determine how LprG and Rv1410c regulate lipid transport to the mycomembrane and (2) Determine how LprG-Rv1410c regulates the addition of mycolic acid-bearing virulence factors to the mycomembrane. Our innovation is to test a novel model for mycomembrane biogenesis and to do so we will leverage our expertise in mycobacteriology and lipid biochemistry to achieve our long-term goal of understanding lipid transport processes that enable the mycomembrane to form and contribute to virulence. The successful completion of these Specific Aims will provide important advances in our understanding of a virulence-associated pathway that mediates these processes in the Mtb cell envelope.
项目摘要 为了根除结核病,世界卫生组织建议将结核病相关死亡人数从 到2025年,每年从100万人减少到5万人。这95%的削减将无法通过目前的方案来实现。因此 消除结核病的战略计划强调开发针对致病细菌的新药, 结核分枝杆菌(Mtb)。因此,Mtb细胞包膜已经成为许多努力的目标,以寻找新的抗结核药物。 抗结核病治疗。然而,新靶点的发现和验证受到我们有限的 了解细胞膜是如何形成的。 酶,使菌膜脂质已被表征,但随后的脂质的机制, 掺入到菌膜中仍然不清楚。我们和其他人已经确定了一条途径, 所需的运输和合成的各种菌膜脂质。 基于我们已发表的工作和初步数据,我们假设脂蛋白LprG和膜 蛋白Rv 1410 c通过介导转运的关键步骤在菌膜生物合成中发挥广泛作用 脂质越过细胞质膜进入菌膜。为了测试这个模型,我们将继续 以下目标: (1)确定LprG和Rv 1410 c如何调节脂质转运到菌膜,以及(2)确定LprG和Rv 1410 c如何调节脂质转运到菌膜, LprG-Rv 1410 c调节向菌膜添加携带分枝菌酸的毒力因子。我们 创新是为了测试一种新的菌膜生物发生模型,为此,我们将利用我们的专业知识 在分枝杆菌学和脂质生物化学中,以实现我们理解脂质转运的长期目标 使菌膜形成并有助于毒性的过程。圆满完成 这些特定的目标将为我们理解一个与药物相关的途径提供重要的进展 在结核分枝杆菌细胞包膜中介导这些过程。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Chuang Seeliger其他文献

Jessica Chuang Seeliger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Chuang Seeliger', 18)}}的其他基金

Untangling the Inner Workings of the Mycobacterial Cell Envelope
解开分枝杆菌细胞膜的内部运作
  • 批准号:
    10004671
  • 财政年份:
    2018
  • 资助金额:
    $ 35.89万
  • 项目类别:
Untangling the Inner Workings of the Mycobacterial Cell Envelope
解开分枝杆菌细胞膜的内部运作
  • 批准号:
    10248369
  • 财政年份:
    2018
  • 资助金额:
    $ 35.89万
  • 项目类别:
Untangling the Inner Workings of the Mycobacterial Cell Envelope
解开分枝杆菌细胞膜的内部运作
  • 批准号:
    10478137
  • 财政年份:
    2018
  • 资助金额:
    $ 35.89万
  • 项目类别:
Cell Envelope Biogenesis in Mycobacterium tuberculosis
结核分枝杆菌的细胞包膜生物发生
  • 批准号:
    10477002
  • 财政年份:
    2018
  • 资助金额:
    $ 35.89万
  • 项目类别:
Cell Envelope Biogenesis in Mycobacterium tuberculosis
结核分枝杆菌的细胞包膜生物发生
  • 批准号:
    9980785
  • 财政年份:
    2018
  • 资助金额:
    $ 35.89万
  • 项目类别:
Exploration of the Mycobacterial Cell Envelope Proteome by Protein Labeling in Live Cells
通过活细胞中的蛋白质标记探索分枝杆菌细胞包膜蛋白质组
  • 批准号:
    9284380
  • 财政年份:
    2016
  • 资助金额:
    $ 35.89万
  • 项目类别:
Exploration of the Mycobacterial Cell Envelope Proteome by Protein Labeling in Live Cells
通过活细胞中的蛋白质标记探索分枝杆菌细胞包膜蛋白质组
  • 批准号:
    9166299
  • 财政年份:
    2016
  • 资助金额:
    $ 35.89万
  • 项目类别:
Inducible Gene Regulation in Mycobacteria
分枝杆菌的诱导基因调控
  • 批准号:
    8582921
  • 财政年份:
    2013
  • 资助金额:
    $ 35.89万
  • 项目类别:
Inducible Gene Regulation in Mycobacteria
分枝杆菌的诱导基因调控
  • 批准号:
    8720686
  • 财政年份:
    2013
  • 资助金额:
    $ 35.89万
  • 项目类别:

相似海外基金

Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
  • 批准号:
    2902098
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Studentship
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
  • 批准号:
    EP/Z533026/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Research Grant
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
  • 批准号:
    BB/Y004035/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Research Grant
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
  • 批准号:
    EP/Y023528/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
  • 批准号:
    FT230100468
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    ARC Future Fellowships
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
  • 批准号:
    BB/Y007611/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
  • 批准号:
    MR/Y033809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
  • 批准号:
    494853
  • 财政年份:
    2023
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
  • 批准号:
    2884862
  • 财政年份:
    2023
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
  • 批准号:
    2904356
  • 财政年份:
    2023
  • 资助金额:
    $ 35.89万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了